Veuillez vous connecter pour accéder à cette page.
Veuillez vous connecter pour accéder à cette page.
Europharm International Business Meeting in Prague, 24–26 February 2027. Where business meets friendship.
Meetings & Webinars

Europharm SMC International Business Meeting 2027

Join us for the Europharm International Business Meeting 2027 in Prague!

Are you ready to expand your network and seize new business opportunities?

Join Europharm SMC in Prague for two days of insightful lectures, strategic B2B meetings and unparalleled networking with leading SMEs in the pharmaceutical sector.


Why should you attend?

Europharm SMC is the recognised voice of European pharmaceutical SMEs, actively engaging with the European Commission and EMA to ensure your interests are heard.


More than 80 decision-makers from across Europe will gather in Prague – don’t miss the chance to be part of this influential community.


The Very Early Bird Rate is only available until 24th November 2026 – with limited seats at this price.


Your registration includes access to expert-led insightful lectures,  exclusive B2B meetings and our prestigious Gala Dinner.


Dates
24–26 February 2027
Venue
NH Collection Prague
Mozartova 261/1, 15000 Prague Czech Republic
Prague, Czech Republic
Visit venue website →
Online payment and bank transfer are both available during registration.
Programme

Programme overview

Day 1 · 19.00 - 20.30
Welcome Drink in the Foyer
networking
Day 2 · 08.30 - 09.00
Registration
registration
Day 2 · 09.00 - 09.10
Welcome
Alain Verrijdt
welcome
Day 2 · 09.10 - 10.15
Opening Speech
Telma Costa
opening
Day 2 · 09:30 - 10.15
The Pharmaceutical Industry Drives Innovation: Central and Eastern European Market Trends 2026 and Beyond
Stefan Lutzmayer

This presentation provides a data-driven perspective on pharmaceutical markets in Central and Eastern Europe, covering key developments across the Rx and OTC segments and overall market performance. It includes benchmarking of mid-sized pharmaceutical companies against large market players and highlights key success factors, growth opportunities, and innovation trends relevant to pharmaceutical SMEs.

Presented at the Europharm SMC Annual Meeting in Prague, the session will offer insights to help participants better understand regional market dynamics and identify opportunities for business development and cross-border collaboration.

The insights are based on analyses by IQVIA, a leading global provider of healthcare data, analytics, and technology solutions, supporting stakeholders across the life sciences and healthcare ecosystem.

lecture session
Day 2 · 10.15 - 10.45
Key success factors for pharmaceutical companies in Eastern Countries
lecture session
Day 2 · 10.45 - 11.15
Coffee Break
networking
Day 2 · 11.15 - 12.00
Latest Update on the Legislative Framework and Its Impact on SMEs
Leonor Enes

This session will provide the latests updates and an overview of the evolving EU legislative framework and its implications for small and medium-sized pharmaceutical enterprises. It will highlight key regulatory changes, upcoming requirements, and their practical impact on SME development, compliance, and market access. Particular attention will be given to challenges and opportunities for innovation. The presentation will also outline how SMEs can anticipate and prepare for these changes. Finally, it will emphasise the importance of dialogue and support mechanisms at EMA.

lecture session
Day 2 · 12.00 - 12.30
Round Table discussion: AI in Pharma: a transformative Pilot in Market Access
Henri Jonckheere
lecture session
Day 2 · 12.30 - 13.00
Europharm SMC Presentation
lecture session
Day 2 · 13.00 - 14.30
Lunch
networking
Day 2 · 14.30 - 15.00
Regulatory Authority PV Inspections – What are they looking at and are you Ready?
Graeme Ladds

Regulatory Inspections are not a Company audit, they are not for your benefit, but the Regulators, ensuring you already have compliant systems to protect patients from all medicines, generic or otherwise.
This presentation looks at the preparation, findings from the EMA for 2025 and the cost of having an Inspection – with and without findings.
Also, there will be coverage of the new PV Module changes and their impact on processes and Regulatory expectations.

lecture
Day 2 · 15.00 - 15.15
Tecnifar: Partnering for What’s Next
Cibele Nomura, Cecilia Pinto

Tecnifar is looking to build partnerships that bring innovative healthcare solutions to patients. This presentation will outline our licensing-in interests and licensing-out opportunities, alongside our openness to co-development collaborations. By combining complementary expertise and capabilities, we aim to advance promising projects and create shared value with our partners.

company presentation
Day 2 · 15.15 - 15.30
Not another “What we do” presentation. Promise
Harry Balanos

Meet Eminvest through the stories a standard company presentation tends to leave out.
Three friends, one plan: build a company, grow it, sell it - and start again. Then do it again. New categories, new products, the right people, the right investments - and happy customers along the way.
So, what’s their secret?”

company presentatin
Day 2 · 15:30 - 15:45
Your Best Next Product May Already Be in Your Portfolio
Francisco Castro

Every pharma company has molecules with untapped potential: new indications, new formulations, new patient populations.
What if you could unlock them without starting from zero?
At VECTORB2B, we guide products through their next evolution, from repurposing strategy, toxicology and proof of concept to clinical trials and real-world evidence, backed by a network of scientific, preclinical and clinical expertise.
In 10 minutes, we’ll show how this end-to-end approach turns existing assets into new opportunities, and the partnerships we’re looking for.
Ten minutes that may change how you look at your portfolio.

company presentation
Day 2 · 19.30 - 20.00
Departure from the hotel by bus
incentive program
Day 2 · 20.00 - 22.30
Evening Gala Dinner
incentive program
Day 3 · 09.00 - 13.00
Pre-arranged One-to-One business Meeting (Session 1)
business
Day 3 · 13.00 - 14.00
Lunch
networking
Day 3 · 14.00 - 16.30
Pre-arranged One-to-One business Meeting (Session 2)
networking
Speakers

Speakers and contributors

Alain Verrijdt

Welcome

Alain Verrijdt, Managing Director Europharm smc
Europharm smc · Belgium
Telma Costa

Opening Speech

Telma Costa, President Europharm smc
Tecnifar · Portugal
Stefan Lutzmayer

The Pharmaceutical Industry Drives Innovation: Central and Eastern European Market Trends 2026 and Beyond

This presentation provides a data-driven perspective on pharmaceutical markets in Central and Eastern Europe, covering key developments across the Rx and OTC segments and overall market performance. It includes benchmarking of mid-sized pharmaceutical companies against large market players and highlights key success factors, growth opportunities, and innovation trends relevant to pharmaceutical SMEs.

Presented at the Europharm SMC Annual Meeting in Prague, the session will offer insights to help participants better understand regional market dynamics and identify opportunities for business development and cross-border collaboration.

The insights are based on analyses by IQVIA, a leading global provider of healthcare data, analytics, and technology solutions, supporting stakeholders across the life sciences and healthcare ecosystem.

Stefan Lutzmayer, Senior Consultant IQVIA
IQVIA · Germany
Leonor Enes

Latest Update on the Legislative Framework and Its Impact on SMEs

This session will provide the latests updates and an overview of the evolving EU legislative framework and its implications for small and medium-sized pharmaceutical enterprises. It will highlight key regulatory changes, upcoming requirements, and their practical impact on SME development, compliance, and market access. Particular attention will be given to challenges and opportunities for innovation. The presentation will also outline how SMEs can anticipate and prepare for these changes. Finally, it will emphasise the importance of dialogue and support mechanisms at EMA.

Leonor Enes, Scientific Senior Specialist
EMA
Henri Jonckheere

AI in Pharma: a transformative Pilot in Market Access

Representative demo presentation by Henri Jonckheere.

Henri Jonckheere, Administrator
MAEVH sas · France
Graeme Ladds

Regulatory Authority PV Inspections – What are they looking at and are you Ready?

Regulatory Inspections are not a Company audit, they are not for your benefit, but the Regulators, ensuring you already have compliant systems to protect patients from all medicines, generic or otherwise.
This presentation looks at the preparation, findings from the EMA for 2025 and the cost of having an Inspection – with and without findings.
Also, there will be coverage of the new PV Module changes and their impact on processes and Regulatory expectations.

Graeme Ladds, PhD; TOPRA; DIA; PIPA; IOD; MAPS; RQA, Pharsafer CEO & Owner
Pharsafer ltd · United Kingdom
Cibele Nomura

Tecnifar: Partnering for What’s Next

Tecnifar is looking to build partnerships that bring innovative healthcare solutions to patients. This presentation will outline our licensing-in interests and licensing-out opportunities, alongside our openness to co-development collaborations. By combining complementary expertise and capabilities, we aim to advance promising projects and create shared value with our partners.

Cibele Nomura, Business Development Manager Licensing-In
Tecnifar · Portugal
Cecilia Pinto

Tecnifar: Partnering for What’s Next

Cecilia Pinto, Regulatory Science, Local Safety Contact & BD manager – Licensing-out
Tecnifar · Portugal
Harry Balanos

Not another “What we do” presentation. Promise

Meet Eminvest through the stories a standard company presentation tends to leave out.
Three friends, one plan: build a company, grow it, sell it - and start again. Then do it again. New categories, new products, the right people, the right investments - and happy customers along the way.
So, what’s their secret?”

Harry Balanos, Business Development Manager
Eminvest Pharmaceuticals srl · Romania
Francisco Castro

Your Best Next Product May Already Be in Your Portfolio

Every pharma company has molecules with untapped potential: new indications, new formulations, new patient populations.
What if you could unlock them without starting from zero?
At VECTORB2B, we guide products through their next evolution, from repurposing strategy, toxicology and proof of concept to clinical trials and real-world evidence, backed by a network of scientific, preclinical and clinical expertise.
In 10 minutes, we’ll show how this end-to-end approach turns existing assets into new opportunities, and the partnerships we’re looking for.
Ten minutes that may change how you look at your portfolio.

Francisco Castro, CEO
VectorB2B · Portugal